Six years in, long Covid is still with many Vermonters — and they say the system is failing them

Long Covid patients in Vermont report debilitating, multi-system symptoms with no clear diagnostics or proven therapies, leaving many unable to work and reliant on a strained healthcare system; a 2023 state report found about 11% of adults who tested positive experienced symptoms lasting three months or longer. Rising costs and benefit uncertainty — marketplace premiums have more than doubled, patients cite drug costs up to $80,000/year, and insurers are denying or refusing reauthorization for treatments — coincide with policy setbacks, including a stalled $1 billion NIH proposal and the HHS elimination of a long Covid research office. The combination of patient demand for coordinated multi-specialty care, regulatory uncertainty and constrained access points to sector-specific opportunities and risks in specialty care, therapeutics and insurers, but limited immediate broad-market impact.

Analysis

Market structure: Persistent long Covid creates durable demand for diagnostics, multispecialty outpatient clinics, telehealth and home-health services as patients require repeat testing, care coordination and pacing strategies. Winners: large diagnostics (DGX, LH), telehealth (TDOC), integrated care/managed care platforms (UNH/Optum) and home-health providers (AMED, OPCH) that can scale interdisciplinary care; losers: small regional hospitals and payers with limited specialty networks who face rising chronic claims and denials. Expect pricing power for specialized infusion and novel outpatient therapies if payers approve them, while broad elective-revenue streams remain pressured by higher premiums.

Risk assessment: Major tail risks include abrupt federal funding cuts or regulatory moves reducing research (already signaled by HHS restructuring) and large-scale payer coverage denials leading to litigation or write-downs for providers; probability moderate, impact high over 12–36 months. Short-term (0–3 months) operational risk: staffing shortages and prior-authorization denials that can delay revenue; medium-term (3–12 months): state/federal policy shifts and insurer rate-setting; long-term (>12 months): emergence of validated diagnostics/therapies could re-rate winners. Hidden dependency: patient ability to pay and subsidy availability is a lever — if marketplace subsidies shrink by >20–30%, utilization of pricey outpatient therapies could fall substantially.

Key Decisions for Investors

• Establish a 1–3% tactical long position in Quest Diagnostics (DGX) or LabCorp (LH) over 3–9 months; use 3–6 month call spreads to limit capital outlay and target a 20–35% upside if outpatient testing volumes rise 5–10%.
• Add a 1–2% strategic long in UnitedHealth Group (UNH) via 9–18 month LEAP calls to capture Optum’s pricing and care-management advantage; exit or trim if CMS/Medicaid reimbursements move unfavorably by >5% within 6 months.
• Take a 1% long in Teladoc Health (TDOC) using 3–6 month call spreads (buy calls financed with OTM calls) to play telehealth demand; cover if monthly active user growth stalls below +2% MoM for two consecutive months.
• Implement a pair trade: long 1% Amedisys (AMED) vs short 1% Community Health Systems (CYH) over 6–12 months to play shift to home health; unwind if AMED outpatient revenue growth <3% YoY or CYH EBITDA margin expands >200 bps.
• Monitor HHS policy, CMS national coverage decisions and Congressional appropriations on long Covid research over the next 30–90 days; if funding is restored or a national coverage memo for outpatient therapies is issued, add to biotech/diagnostic exposure (increase positions by 50%).